Metsera (MTSR) Stock Overview
A clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MTSR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Metsera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$63.04 |
| 52 Week High | US$66.10 |
| 52 Week Low | US$12.30 |
| Beta | 0 |
| 1 Month Change | 20.95% |
| 3 Month Change | 80.68% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 137.89% |
Recent News & Updates
Metsera Becomes The Prize In Obesity's Biggest Bidding War
Oct 30Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans
Jul 31
Shareholder Returns
| MTSR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 20.1% | 3.1% | 0.5% |
| 1Y | n/a | 3.9% | 20.0% |
Return vs Industry: Insufficient data to determine how MTSR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MTSR performed against the US Market.
Price Volatility
| MTSR volatility | |
|---|---|
| MTSR Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MTSR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MTSR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 107 | Whit Bernard | metsera.com |
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Metsera, Inc. Fundamentals Summary
| MTSR fundamental statistics | |
|---|---|
| Market cap | US$6.71b |
| Earnings (TTM) | -US$307.82m |
| Revenue (TTM) | n/a |
Is MTSR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTSR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$307.82m |
| Earnings | -US$307.82m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.92 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MTSR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 18:03 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metsera, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Timothy Anderson | BofA Global Research |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Umer Raffat | Evercore ISI |